FDA Expands Approval for Alnylam’s Drug to Treat Rare Heart Disease
By Reuters The Food and Drug Administration approved Alnylam’s drug to treat a rare and deadly heart disease on Thursday, allowing the entry of a new type of medicine in a market dominated by Pfizer’s blockbuster Vyndaqel. Alnylam is banking on the success of the drug, chemically called vutrisiran, to reach profitability and invest in future treatments. Its drug will compete in the…
More Stories
Harbour Investments Inc. Sells 71 Shares of AppLovin Co. (NASDAQ:APP)
Harbour Investments Inc. lowered its stake in shares of AppLovin Co. (NASDAQ:APP – Free Report) by 45.8% in the fourth...
Signaturefd LLC Sells 4,522 Shares of Smurfit Westrock Ltd (NYSE:SW)
Signaturefd LLC lowered its stake in shares of Smurfit Westrock Ltd (NYSE:SW – Free Report) by 80.7% during the fourth...
JPMorgan Chase & Co. (NYSE:JPM) Shares Acquired by Parallel Advisors LLC
Parallel Advisors LLC lifted its position in JPMorgan Chase & Co. (NYSE:JPM) by 0.9% during the fourth quarter, according to...
Signaturefd LLC Has $18.21 Million Stock Position in JPMorgan Chase & Co. (NYSE:JPM)
Signaturefd LLC increased its stake in JPMorgan Chase & Co. (NYSE:JPM) by 2.8% in the 4th quarter, according to the...
Natixis Advisors LLC Has $1.91 Million Position in CAVA Group, Inc. (NYSE:CAVA)
Natixis Advisors LLC boosted its position in shares of CAVA Group, Inc. (NYSE:CAVA – Free Report) by 54.1% during the...
Cibc World Markets Corp Makes New $355,000 Investment in StepStone Group LP (NASDAQ:STEP)
Cibc World Markets Corp acquired a new stake in shares of StepStone Group LP (NASDAQ:STEP – Free Report) in the...